Pacira Pharma releases more data on the benefits of Exparel

Pacira Pharmaceuticals (PCRX) is out with results from Phase 4 studies of Exparel in laparoscopic colectomy patients.

The company says the data "reinforce findings from [the] IMPROVE trials ... demonstrating the opioid-sparing and economic benefits of Exparel."

Patients receiving the Exparel-based multimodal regimen experienced:"A 64 mg reduction in mean opioid consumption," "a 1-day reduction in median length of hospital stay," "significantly fewer opioid-related adverse events," and "a $1,784 reduction in mean hospitalization costs." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs